SpliceBio Secures Series B Financing to Advance Stargardt Disease Therapy
Deal News | Jun 11, 2025 | Ysios Capital
SpliceBio, a Barcelona-based clinical-stage genetic medicines company, has closed a $135 million Series B round to fund its lead gene therapy candidate, SB-007, which targets Stargardt disease. This inherited retinal disorder results in progressive vision loss and currently has no approved treatments. The financing was led by EQT Life Sciences and Sanofi Ventures and included participation from Roche Venture Fund and existing investors such as Ysios Capital and Novartis Venture Fund. SB-007 is a pioneering dual adeno-associated viral (AAV) gene therapy that has received FDA and UK MHRA clearances. The capital injection will help SpliceBio progress clinical trials and expand its genetic medicine pipeline, including treatments in ophthalmology and neurology. SpliceBio's technology, originating from Princeton University, overcomes AAV vector limitations by utilizing a Protein Splicing platform, enabling the transportation of larger genes by splitting them into two or more transgenes. Investors are joining SpliceBio's board, emphasizing their commitment to its mission to transform the treatment of untreatable diseases.
Sectors
- Biotechnology
- Healthcare
- Pharmaceuticals
Geography
- Spain – SpliceBio is headquartered in Barcelona, Spain, and the article highlights its operations and advancements in genetic medicines originating from this location.
- United States – Several investors like Sanofi Ventures and Roche Venture Fund, and regulatory clearances from the US FDA, play a crucial role in the company’s development.
- United Kingdom – The UK MHRA has provided clearance for SB-007, making the UK a relevant geography in terms of regulatory approval and clinical progress.
Industry
- Biotechnology – The article discusses advancements in genetic medicine therapies, specifically using biotechnology platforms to develop treatments for Stargardt disease and other genetic disorders.
- Healthcare – SpliceBio is engaged in creating genetic therapies that address critical health issues, such as vision loss in Stargardt disease, thereby contributing to advancements in healthcare solutions.
- Pharmaceuticals – The development and clinical testing of SB-007 and other genetic therapies place the company within the pharmaceutical sector, focusing on novel treatments for diseases caused by genetic mutations.
Financials
- $135 million – The total amount raised in SpliceBio's Series B financing round, aimed at advancing its lead program SB-007 for Stargardt disease and expanding its genetic medicine pipeline.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| SpliceBio | Target | Company | A clinical-stage genetic medicines company focused on addressing diseases caused by mutations in large genes using Protein Splicing technology. |
| Ysios Capital | Existing Investor | PE Firm | A venture capital firm included among SpliceBio's investors, specializing in life sciences. |
| EQT Life Sciences | Co-Lead Investor | PE Firm | A venture capital firm that is part of EQT Partners, investing in the life sciences sector and co-leading the funding round. |
| Sanofi Ventures | Co-Lead Investor | PE Firm | A venture capital arm of Sanofi, focused on early-stage investments in the life sciences sector. |
| Roche Venture Fund | Investor | Corporate Venture Fund | The corporate venture capital fund of Roche, investing in innovative life science companies. |
| Miquel Vila-Perell, Ph.D. | Chief Executive Officer | Person | CEO and Co-Founder of SpliceBio, overseeing the company’s strategic direction and corporate operations. |
| Daniela Begolo | Board Member | Person | Managing Director at EQT Life Sciences, joining SpliceBio’s board after the Series B funding. |
| Laia Crespo | Board Member | Person | Partner at Sanofi Ventures, joining SpliceBio’s board after the Series B funding. |
| Carole Nuechterlein | Board Member | Person | Head of Roche Venture Fund, joining SpliceBio’s board following the Series B round. |